This case report explores methylene blue as a potential treatment for post-cardiac arrest refractory shock, a condition with over 50% mortality and few evidence-based options. While methylene blue has shown promise in post-operative cardiac bypass settings, its use in cardiac arrest outside surgery remains largely unstudied. The case suggests methylene blue may warrant clinical investigation as a therapeutic option for practitioners managing critically ill post-arrest patients.
For your business
Methylene blue may offer a management option for post-arrest refractory shock when standard vasopressors fall short.